The cost of diabetes chronic complications among Iranian people with type 2 diabetes mellitus

被引:28
作者
Farshchi A. [1 ]
Esteghamati A. [2 ]
Sari A.A. [3 ]
Kebriaeezadeh A. [1 ]
Abdollahi M. [4 ]
Dorkoosh F.A. [1 ]
Khamseh M.E. [5 ]
Aghili R. [5 ]
Keshtkar A. [6 ]
Ebadi M. [2 ]
机构
[1] Department of Pharmacoeconomics and Pharmaceutical Administration, School of Pharmacy, Tehran University of Medical Sciences, Tehran
[2] Endocrinology and Metabolism Research Center (EMRC), Vali-Asr Hospital, Tehran University of Medical Sciences, Tehran
[3] Department of Health Management and Economics, Tehran University of Medical Sciences, Tehran
[4] Department of Toxicology and Pharmacology, School of Pharmacy and Pharmaceutical Sciences Research Center, Tehran University of medical Sciences, Tehran
[5] Endocrine Research Center, Institute of Endocrinology and Metabolism, Iran University of Medical Sciences, Tehran
[6] Osteoporosis Research Center, Endocrinology and Metabolism Research Institute, Tehran University of Medical Sciences, Tehran
关键词
Complication; Cost; HbA1c; Productivity; QALY; Type 2 diabetes mellitus;
D O I
10.1186/2251-6581-13-42
中图分类号
学科分类号
摘要
Background: To evaluate the cost of diabetes related micro- and macrovascular complications in Iranian people with type 2 diabetes mellitus.Methods: In routine clinical practice, people with type 2 diabetes mellitus were assessed for 10 years at a diabetes care center. The type of medications and clinical data were extracted from patients' documents. Mortality rate and the incidence of micro- and macrovascular complications recorded in patients' documents were analyzed. Cost analysis was comprised of 1) para clinic costs as well as laboratory, medications, clinical visits and nonmedical costs 2) inpatient costs as well as hospital admission costs, disability, and mortality costs.Results: From 1562 people with type 2 diabetes mellitus, a total of 1000 patients with mean duration disease of 11.2 years, who had completed information in their documents, were studied. All people were free from complications at baseline. Mean cumulative incidence of diabetes-related complications over 10 years were 10.9 ± 3.5%, 8.0 ± 3.1%, 4.6 ± 1.7%, 9.1 ± 3.6% and 2.3 ± 0.9% for peripheral neuropathy and diabetic foot ulcer, nephropathy, ophthalmic complications, cardiovascular disease and death, respectively. People with better glycemic control had less complication and also related expenditures. Average para clinic cost per patient was 393.6 ± 47.8 and average inpatient cost per patient was 1520.7 ± 104.5 USD.Conclusions: Our findings demonstrate considerable incidence of diabetes chronic complications and also high health care expenditure for related complications among our patients. As the number of people with diabetes continues to rise, early detection of the disease and implementation of timely and appropriate therapeutic strategies could decrease the burden of diabetes chronic complications and also huge related expenditures. © 2014 Farshchi et al.; licensee BioMed Central Ltd.
引用
收藏
相关论文
共 59 条
[1]
Esteghamati A., Gouya M.M., Abbasi M., Delavari A., Alikhani S., Alaedini F., Safaie A., Forouzanfar M., Gregg E.W., Prevalence of Diabetes and Impaired Fasting Glucose in the Adult Population of Iran National Survey of Risk Factors for Non-Communicable Diseases of Iran, Diabetes Care, 31, 1, pp. 96-98, (2008)
[2]
Aghili R., Khamseh M.E., Malek M., Yarahmadi S., Farshchi A., Structured self monitoring of blood glucose in Iranian people with type 2 diabetes
[3]
A cost consequence analysis, DARU Journal of Pharmaceutical Sciences, 20, 1, pp. 1-6, (2012)
[4]
Boushehri E., Khamseh M.E., Farshchi A., Aghili R., Malek M., Ebrahim Valojerdi A., Effects of morning report case presentation on length of stay and hospitalisation costs, Medical education, 47, 7, pp. 711-716, (2013)
[5]
The Global Burden
[6]
Farshchi A., Nikfar S., Seyedifar M., Abdollahi M., Effect of Chromium on Glucose and Lipid Profiles in Patients with Type 2 Diabetes
[7]
A Meta-analysis Review of Randomized Trials, Journal of Pharmacy & Pharmaceutical Sciences, 16, 1, pp. 99-114, (2013)
[8]
Farshchi A., Nikfar S., Abdollahi M., Concerns on the use of chromium in type 2 diabetes mellitus
[9]
needs to conduct major meta-analysis, Int J Pharmacol, 8, 6, pp. 470-472, (2012)
[10]
Standards of medical care in diabetes-2013, Diabetes Care, 36, pp. S11-S66, (2013)